drugset
Drugs / (R)-9b
last change Mar 2026 re-read 3 minutes ago

(R)-9b

Small molecule targets TNK2 via inhibition

Developed for
prostate carcinoma
Investigated by
National Cancer Institute (NCI) · TechnoGenesys, Inc. · University of Wisconsin, Madison · Washington University School of Medicine

Trials 1

today NCT06705686 · Ph 1
20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06705686 Mar 2026 → Dec 2027 expected prostate carcinoma TechnoGenesys, Inc. Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as (R)-9b ClinicalTrials.gov intervention name — accepted as the source's own label NCT06705686 ↗
Action Inhibit “TNK2 inhibitor, (R)-9b reversed this process and induced mitophagy-based autophagy to mitigate prostate tumor growth while sparing normal prostate cells.” PMID 35895804 ↗ Jul 2022
Modality Small molecule “An ACK1 small-molecule inhibitor, (R)-9b, recapitulates inhibition of ICB-resistant tumours” PMID 36376335 ↗ Nov 2022
Route Oral “(R)-9bMS will be taken by mouth twice daily” NCT06705686 ↗
Target TNK2 “TNK2 inhibitor, (R)-9b reversed this process and induced mitophagy-based autophagy to mitigate prostate tumor growth while sparing normal prostate cells.” PMID 35895804 ↗ Jul 2022